Literature DB >> 31065858

Clinical and laboratory features of African-Brazilian patients with systemic sclerosis.

Cristiane Mendes1,2, Vilma S T Viana1, Sandra G Pasoto1, Elaine P Leon1, Eloisa Bonfa1, Percival D Sampaio-Barros3,4.   

Abstract

OBJECTIVE: African-Brazilians comprise a group of blacks and "pardos." As racial differences can be associated with distinct presentations, we evaluated the clinical and serological associations of African-Brazilians with systemic sclerosis (SSc).
METHODS: Sera from 260 adult SSc patients (203 whites and 57 African-Brazilians) were evaluated. Patients with overlap syndromes were excluded. Clinical and demographic data were obtained from an electronic register database. Laboratory analysis included the following: anti-CENP-A/CENP-B, Scl70, RNA polymerase III, Ku, fibrillarin, Th/To, PM-Scl75, and PM-Scl100 by line immunoassay and anti-nuclear antibodies (ANA) by indirect immunofluorescence (IIF) on HEp-2 cells.
RESULTS: African-Brazilian SSc patients presented shorter disease duration (12.8 ± 6.5 vs. 15.9 ± 8.1 years, p = 0.009), higher frequency of nucleolar ANA pattern (28% vs. 13%, p = 0.008), and lower frequencies of centromeric ANA pattern (14% vs. 29%, p = 0.026) and CENP-B (18% vs. 34%, p = 0.017), as well as an association with severe interstitial lung disease (58% vs. 43%; p = 0.044). Further comparison of ethnic groups according to subsets revealed that diffuse SSc African-Brazilian patients presented higher frequency of pulmonary hypertension (p = 0.017), heart involvement (p = 0.037), nucleolar ANA pattern (p = 0.036), anti-fibrillarin antibodies (p = 0.037), and higher mortality (48% vs. 19%; p = 0.009). A different pattern was observed for the limited subset with solely a lower frequency of esophageal involvement (p = 0.050) and centromeric ANA pattern (p = 0.049). Survival analysis showed that African-Brazilians had a higher mortality, when adjusted for age, gender, and clinical subset (RR 2.06, CI 95% 1.10-3.83, p = 0.023).
CONCLUSION: African-Brazilians have distinct characteristics according to clinical subset and an overall more severe SSc than whites, similar to the blacks from other countries.Key Points • African-Brazilian SSc patients were associated with severe interstitial lung disease and nucleolar ANA pattern when compared to white SSc patients. • When disease subsets were considered, African-Brazilian patients with diffuse SSc presented association with pulmonary hypertension, heart involvement, nucleolar ANA pattern, and anti-fibrillarin antibodies. • White SSc patients were associated with centromeric ANA pattern. • Survival analysis at 5, 10, 15, and 20 years, adjusted for age, gender, and disease subset, was significantly worse in African-Brazilian SSc patients.

Entities:  

Keywords:  African-Brazilians; Autoantibodies; Diffuse scleroderma; Ethnicity; Limited scleroderma; Systemic sclerosis

Mesh:

Substances:

Year:  2019        PMID: 31065858     DOI: 10.1007/s10067-019-04575-5

Source DB:  PubMed          Journal:  Clin Rheumatol        ISSN: 0770-3198            Impact factor:   2.980


  37 in total

Review 1.  Genetic analysis of African populations: human evolution and complex disease.

Authors:  Sarah A Tishkoff; Scott M Williams
Journal:  Nat Rev Genet       Date:  2002-08       Impact factor: 53.242

Review 2.  Diagnostic accuracy and predictive value of extended autoantibody profile in systemic sclerosis.

Authors:  Danilo Villalta; Tiziana Imbastaro; Sabrina Di Giovanni; Ciro Lauriti; Marco Gabini; Maria Costanza Turi; Nicola Bizzaro
Journal:  Autoimmun Rev       Date:  2012-07-07       Impact factor: 9.754

3.  2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative.

Authors:  Frank van den Hoogen; Dinesh Khanna; Jaap Fransen; Sindhu R Johnson; Murray Baron; Alan Tyndall; Marco Matucci-Cerinic; Raymond P Naden; Thomas A Medsger; Patricia E Carreira; Gabriela Riemekasten; Philip J Clements; Christopher P Denton; Oliver Distler; Yannick Allanore; Daniel E Furst; Armando Gabrielli; Maureen D Mayes; Jacob M van Laar; James R Seibold; Laszlo Czirjak; Virginia D Steen; Murat Inanc; Otylia Kowal-Bielecka; Ulf Müller-Ladner; Gabriele Valentini; Douglas J Veale; Madelon C Vonk; Ulrich A Walker; Lorinda Chung; David H Collier; Mary Ellen Csuka; Barri J Fessler; Serena Guiducci; Ariane Herrick; Vivien M Hsu; Sergio Jimenez; Bashar Kahaleh; Peter A Merkel; Stanislav Sierakowski; Richard M Silver; Robert W Simms; John Varga; Janet E Pope
Journal:  Arthritis Rheum       Date:  2013-10-03

4.  Anti-fibrillarin antibody in African American patients with systemic sclerosis: immunogenetics, clinical features, and survival analysis.

Authors:  Roozbeh Sharif; Marvin J Fritzler; Maureen D Mayes; Emilio B Gonzalez; Terry A McNearney; Hilda Draeger; Murray Baron; Daniel E Furst; Dinesh K Khanna; Deborah J del Junco; Jerry A Molitor; Elena Schiopu; Kristine Phillips; James R Seibold; Richard M Silver; Robert W Simms; Marilyn Perry; Carlos Rojo; Julio Charles; Xiaodong Zhou; Sandeep K Agarwal; John D Reveille; Shervin Assassi; Frank C Arnett
Journal:  J Rheumatol       Date:  2011-05-15       Impact factor: 4.666

5.  Six-minute walk test for the evaluation of pulmonary disease severity in scleroderma patients.

Authors:  Wander O Villalba; Percival D Sampaio-Barros; Mônica C Pereira; Elza M F P Cerqueira; Cid A Leme; João F Marques-Neto; Ilma A Paschoal
Journal:  Chest       Date:  2007-01       Impact factor: 9.410

6.  The modified Rodnan skin score is an accurate reflection of skin biopsy thickness in systemic sclerosis.

Authors:  D E Furst; P J Clements; V D Steen; T A Medsger; A T Masi; W A D'Angelo; P A Lachenbruch; R G Grau; J R Seibold
Journal:  J Rheumatol       Date:  1998-01       Impact factor: 4.666

7.  Clinical and laboratory manifestations of systemic sclerosis (scleroderma) in Black South Africans.

Authors:  R E Tager; M Tikly
Journal:  Rheumatology (Oxford)       Date:  1999-05       Impact factor: 7.580

Review 8.  Race and association with disease manifestations and mortality in scleroderma: a 20-year experience at the Johns Hopkins Scleroderma Center and review of the literature.

Authors:  Allan C Gelber; Rebecca L Manno; Ami A Shah; Adrianne Woods; Elizabeth N Le; Francesco Boin; Laura K Hummers; Fredrick M Wigley
Journal:  Medicine (Baltimore)       Date:  2013-07       Impact factor: 1.889

9.  Severity of systemic sclerosis-associated pulmonary arterial hypertension in African Americans.

Authors:  Isabel Blanco; Stephen Mathai; Majid Shafiq; Danielle Boyce; Todd M Kolb; Hala Chami; Laura K Hummers; Traci Housten; Neal Chaisson; Ari L Zaiman; Fredrick M Wigley; Ryan J Tedford; David A Kass; Rachel Damico; Reda E Girgis; Paul M Hassoun
Journal:  Medicine (Baltimore)       Date:  2014-07       Impact factor: 1.889

10.  Clinical relevance of HEp-2 indirect immunofluorescent patterns: the International Consensus on ANA patterns (ICAP) perspective.

Authors:  Jan Damoiseaux; Luis Eduardo Coelho Andrade; Orlando Gabriel Carballo; Karsten Conrad; Paulo Luiz Carvalho Francescantonio; Marvin J Fritzler; Ignacio Garcia de la Torre; Manfred Herold; Werner Klotz; Wilson de Melo Cruvinel; Tsuneyo Mimori; Carlos von Muhlen; Minoru Satoh; Edward K Chan
Journal:  Ann Rheum Dis       Date:  2019-03-12       Impact factor: 19.103

View more
  5 in total

1.  Recent advances steer the future of systemic sclerosis toward precision medicine.

Authors:  Gemma Lepri; Michael Hughes; Cosimo Bruni; Marco Matucci Cerinic; Silvia Bellando Randone
Journal:  Clin Rheumatol       Date:  2019-11-23       Impact factor: 2.980

Review 2.  Clinical Significance of Antinucleolar Antibodies: Biomarkers for Autoimmune Diseases, Malignancies, and others.

Authors:  Minoru Satoh; Angela Ceribelli; Tomoko Hasegawa; Shin Tanaka
Journal:  Clin Rev Allergy Immunol       Date:  2022-03-08       Impact factor: 10.817

3.  Development of Pulmonary Hypertension in Over One-Third of Patients With Th/To Antibody-Positive Scleroderma in Long-Term Follow-Up.

Authors:  Shashank Suresh; Devon Charlton; Erin K Snell; Maureen Laffoon; Thomas A Medsger; Lei Zhu; Robyn T Domsic
Journal:  Arthritis Rheumatol       Date:  2022-07-21       Impact factor: 15.483

4.  Is exposure to environmental factors associated with a characteristic clinical and laboratory profile in systemic sclerosis? A retrospective analysis.

Authors:  Lisbeth A Aguila; Henrique Carriço da Silva; Ana Cristina Medeiros-Ribeiro; Bruna Giusto Bunjes; Ana Paula Luppino-Assad; Percival D Sampaio-Barros
Journal:  Rheumatol Int       Date:  2020-08-30       Impact factor: 2.631

5.  Pulmonary hypertension in systemic sclerosis: diagnosis by systematic screening and prognosis after three years follow-up.

Authors:  Verônica Silva Vilela; Marcio Macri Dias; Ângelo Antunes Salgado; Bruno Rangel Antunes da Silva; Agnaldo José Lopes; Elizabeth Jauhar Cardoso Bessa; Leonardo Palermo Bruno; Cláudia Henrique da Costa; Roger Abramino Levy; Rogério Rufino
Journal:  BMC Pulm Med       Date:  2021-07-29       Impact factor: 3.317

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.